Drug Trial Radar · NCT01314872
A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008)
Last checked: Nov 20, 2026Latest source record: Feb 4, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,395
Actual
Start
Mar 31, 2011
Primary completion
Oct 22, 2012
Study completion Oct 10, 2013
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Mar 15, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 2-part study to assess if vibegron (MK-4618) reduces the number of daily urinations more effectively than placebo in participants with overactive bladder (OAB). The primary hypothesis of the base study is that administration of vibegron demonstrates a dose-related reduction, compared with placebo, in average number of daily micturitions in participants with OAB after 8 weeks of treatment.
Conditions
- Urinary Bladder, Overactive
Interventions
VibegronDrug
Participants received vibegron oral tablets at dosages of 3 mg, 15 mg, 50 mg, or 100 mg depending on their vibegron arm assignment, taken orally each morning.
Tolterodine ERDrug
Participants received one tolterodine ER 4 mg capsule, taken orally once a day.
Placebo matching vibegronDrug
Participants received placebo matching vibegron tablets, taken orally each morning.
Placebo matching tolterodine ERDrug
Participants received placebo matching tolterodine ER capsule, taken orally each morning.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Base Study/Part 1: Change From Baseline in Average Daily Micturitions at Week 8Time frame: Baseline and Week 8
- Base Study/Part 1 + Part 2: Number of Participants Who Experienced an Adverse Event (AE)Time frame: Part 1: up to 8 weeks; Part 2: up to 4 weeks. The time frame was an additional 2 weeks for participants not continuing to the Extension Study.
- Base Study/Part 1 + Part 2: Number of Participants Who Had Study Medication Withdrawn Due to an AETime frame: Part 1: up to 8 weeks; Part 2: up to 4 weeks
- Extension Study: Number of Participants Who Experienced an Adverse Event (AE)Time frame: Extension: up to 54 weeks (including 2-week follow-up)
- Extension Study: Number of Participants Who Had Study Medication Withdrawn Due to an AETime frame: Extension: up to 52 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.